Incensole acetateCAS# 34701-53-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 34701-53-6 | SDF | Download SDF |
| PubChem ID | 73755086 | Appearance | Clear oily liquid |
| Formula | C22H36O3 | M.Wt | 348.5 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Slightly soluble in water | ||
| Chemical Name | (1,5,9-trimethyl-12-propan-2-yl-15-oxabicyclo[10.2.1]pentadeca-5,9-dien-2-yl) acetate | ||
| SMILES | CC1=CCCC(=CCC2(CCC(O2)(C(CC1)OC(=O)C)C)C(C)C)C | ||
| Standard InChIKey | HVBACKJYWZTKCA-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H36O3/c1-16(2)22-13-12-18(4)9-7-8-17(3)10-11-20(24-19(5)23)21(6,25-22)14-15-22/h8,12,16,20H,7,9-11,13-15H2,1-6H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Incensole acetate is a novel anti-inflammatory compound that inhibits NF-κB activation. Incensole acetate has protective effects on cerebral ischemic injury, it can reduce depressive-like behavior and modulate hippocampal BDNF and CRF expression of submissive animals. |
| Targets | NF-kB | TRPV | TGF-β/Smad | TNF-α | IL Receptor |
| In vivo | Protective effects of incensole acetate on cerebral ischemic injury.[Pubmed: 22284622]Brain Res. 2012 Mar 14;1443:89-97. doi: 10.1016/j.brainres.2012.01.001. Epub 2012 Jan 9.The resin of Boswellia species is a major anti-inflammatory agent that has been used for centuries to treat various conditions including injuries and inflammatory conditions. Incensole acetate (IA), a major constituent of this resin, has been shown to inhibit NF-κB activation and concomitant inflammation, as well as the neurological deficit following head trauma. |
| Animal Research | Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals.[Pubmed: 23015543]J Psychopharmacol. 2012 Dec;26(12):1584-93. doi: 10.1177/0269881112458729. Epub 2012 Sep 26.Incensole acetate (IA), a constituent of Boswellia resin ('frankincense'), was previously demonstrated to exhibit an antidepressive-like effect in the Forced Swim Test (FST) in mice following single dose administration (50 mg/kg). |
| Structure Identification | Nat Prod Commun. 2012 Mar;7(3):283-8.Efficient preparation of incensole and incensole acetate, and quantification of these bioactive diterpenes in Boswellia papyrifera by a RP-DAD-HPLC method.[Pubmed: 22545396]Incensole and Incensole acetate, found in incense, are encouraging potent bioactive diterpenic cembrenoids, inhibiting Nuclear Factor-kappaB activation. Furthermore, Incensole acetate elicits psycho-activity in mice by activating the TRPV3 channels in the brain. |
Incensole acetate Dilution Calculator
Incensole acetate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8694 mL | 14.3472 mL | 28.6944 mL | 57.3888 mL | 71.736 mL |
| 5 mM | 0.5739 mL | 2.8694 mL | 5.7389 mL | 11.4778 mL | 14.3472 mL |
| 10 mM | 0.2869 mL | 1.4347 mL | 2.8694 mL | 5.7389 mL | 7.1736 mL |
| 50 mM | 0.0574 mL | 0.2869 mL | 0.5739 mL | 1.1478 mL | 1.4347 mL |
| 100 mM | 0.0287 mL | 0.1435 mL | 0.2869 mL | 0.5739 mL | 0.7174 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 1-Indanamine
Catalog No.:BCN2246
CAS No.:34698-41-4
- TCS 2510
Catalog No.:BCC7853
CAS No.:346673-06-1
- Dehydrodeguelin
Catalog No.:BCN4778
CAS No.:3466-23-7
- Cyperotundone
Catalog No.:BCN8339
CAS No.:3466-15-7
- Amoxicillin Sodium
Catalog No.:BCC4947
CAS No.:34642-77-8
- 1-Methoxycarbonyl-beta-carboline
Catalog No.:BCN5282
CAS No.:3464-66-2
- 2-Benzoyloxy-3-hydroxynortropane
Catalog No.:BCN1872
CAS No.:34622-25-8
- Maltohexaose
Catalog No.:BCN6710
CAS No.:34620-77-4
- Maltopentaose
Catalog No.:BCN8421
CAS No.:34620-76-3
- Maltotetraose
Catalog No.:BCN6709
CAS No.:34612-38-9
- 5-hydroxypyrazine-2-carboxylic acid
Catalog No.:BCC1311
CAS No.:34604-60-9
- AS601245
Catalog No.:BCC6464
CAS No.:345987-15-7
- Ferrostatin-1 (Fer-1)
Catalog No.:BCC2323
CAS No.:347174-05-4
- ITX3
Catalog No.:BCC6066
CAS No.:347323-96-0
- Sodium usnate
Catalog No.:BCN8376
CAS No.:34769-44-3
- Z-Asp(OBzl)-OH
Catalog No.:BCC2791
CAS No.:3479-47-8
- H-D-Met-OH
Catalog No.:BCC2997
CAS No.:348-67-4
- H-Tyr(Bzl)-OMe.HCl
Catalog No.:BCC3132
CAS No.:34805-17-9
- Boc-Met(O)-OH
Catalog No.:BCC3425
CAS No.:34805-21-5
- BAY 57-1293
Catalog No.:BCC4050
CAS No.:348086-71-5
- 8-Acetonyldihydroavicine
Catalog No.:BCN3303
CAS No.:348098-59-9
- Marilactone
Catalog No.:BCN7363
CAS No.:34818-17-2
- 4'-Demethyleucomin
Catalog No.:BCN5283
CAS No.:34818-83-2
- DL-Dithiothreitol
Catalog No.:BCC7586
CAS No.:3483-12-3
Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals.[Pubmed:23015543]
J Psychopharmacol. 2012 Dec;26(12):1584-93.
Incensole acetate (IA), a constituent of Boswellia resin ('frankincense'), was previously demonstrated to exhibit an antidepressive-like effect in the Forced Swim Test (FST) in mice following single dose administration (50 mg/kg). Here, we show that acute administration of considerably lower dose (10 mg/kg) IA to selectively bred mice, showing prominent submissive behavior, exerted significant antidepressant-like effects in the FST. Furthermore, chronic administration of 1 or 5 mg/kg per day of IA for three consecutive weeks dose- and time-dependently reduced the submissiveness of the mice in the Dominant-Submissive Relationship test, developed to screen the chronic effect of antidepressants. This behavioral effect was concomitant to reduced serum corticosterone levels, dose-dependent down-regulation of corticotropin releasing factor and up-regulation of brain derived neurotrophic factor transcripts IV and VI expression in the hippocampus. These data suggest that IA modulates the hypothalamic-pituitary-adrenal (HPA) axis and influences hippocampal gene expression, leading to beneficial behavioral effects supporting its potential as a novel treatment of depressive-like disorders.
Efficient preparation of incensole and incensole acetate, and quantification of these bioactive diterpenes in Boswellia papyrifera by a RP-DAD-HPLC method.[Pubmed:22545396]
Nat Prod Commun. 2012 Mar;7(3):283-8.
Incensole and Incensole acetate, found in incense, are encouraging potent bioactive diterpenic cembrenoids, inhibiting Nuclear Factor-kappaB activation. Furthermore, Incensole acetate elicits psycho-activity in mice by activating the TRPV3 channels in the brain. Starting from crude extracts of the incense species Boswellia papyrifera Hochst., a convenient procedure for the efficient large-scale synthesis of incensole and its acetate is presented. Additionally, a reversed-phase, diode-array-detection, high-performance liquid chromatography (RP-DAD-HPLC) method for the quantification of incensole and Incensole acetate is reported, indicating that these two compounds are typical biomarkers for B. papyrifera.
Protective effects of incensole acetate on cerebral ischemic injury.[Pubmed:22284622]
Brain Res. 2012 Mar 14;1443:89-97.
The resin of Boswellia species is a major anti-inflammatory agent that has been used for centuries to treat various conditions including injuries and inflammatory conditions. Incensole acetate (IA), a major constituent of this resin, has been shown to inhibit NF-kappaB activation and concomitant inflammation, as well as the neurological deficit following head trauma. Here, we show that IA protects against ischemic neuronal damage and reperfusion injury in mice, attenuating the inflammatory nature of ischemic damage. IA given post-ischemia, reduced infarct volumes and improved neurological activities in the mouse model of ischemic injury in a dose dependent fashion. The protection from damage was accompanied by inhibition of TNF-alpha, IL-1beta and TGF-beta expression, as well as NF-kappaB activation following injury. In addition, IA is shown to have a therapeutic window of treatment up to 6h after ischemic injury. Finally, the protective effects of IA were partially mediated by TRPV3 channels as determined by the TRPV3 deficient mice and channel blocker studies. This study suggests that the anti-inflammatory and neuroprotective activities of IA may serve as a novel therapeutic treatment for ischemic and reperfusion injury, and as a tool in the ongoing research of mechanisms for neurological damage.
